Showing results (251-260 of 271) with videos related to

Sort By:
Pageof 28
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2026
Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?Glen M Blake, Ricardo Donners, Amelia E B Moore, et al.
The American Journal of Pathology|October 1, 1996
Role of matrix metalloproteinases in failure to re-epithelialize after corneal injuryM E Fini, W C Parks, W B Rinehart, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2025
An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomicsMitchell Chen, Susan J Copley, Yidong Han, et al.
Chemical Science|September 17, 2025
Maleic anhydride derived diphosphines: adaptable chelators for receptor-targeted 99mTc, 64Cu and 188Re radiotracersRachel E Nuttall, Ingebjørg N Hungnes, Truc T Pham, et al.
Frontiers in Endocrinology|October 2, 2023
Utility of a simplified [18F] sodium fluoride PET imaging method to quantify bone metabolic flux for a wide range of clinical applicationsTanuj Puri, Michelle L Frost, Amelia E B Moore, et al.
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
JNCI Cancer Spectrum|October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess responseChris Parker, Nina Tunariu, Holly Tovey, et al.
Cancers|December 23, 2022
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyDaniel Johnathan Hughes, Matthaios Kapiris, Andreja Podvez Nevajda, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
British Journal of Cancer|April 5, 2025
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancerDaniel Johnathan Hughes, Gitasha Chand, Jessica Johnson, et al.
Pageof 28